Target Information

Target General Infomation
Target ID
T68816
Former ID
TTDI01780
Target Name
VEGF receptor
Target Type
Clinical Trial
Disease Age related macular degeneration [ICD9: 362.5; ICD10: H35.3]
Angina pectoris [ICD9: 413; ICD10: I20]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Diabetic macular edema [ICD9: 250, 362.01, 362.07, 362.53, 782.3; ICD10: E08-E13, E08.3, E09.3, E10.3, E11.3, E13.3, H35.8, R60.9]
Diabetic retinopathy [ICD9: 250.5; ICD10: H36, E10.3, E11.3, E13.3]
Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10: E11.40]
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0]
Psoriasis [ICD9: 696; ICD10: L40]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
BioChemical Class
Kinase
EC Number
EC 2.7.10.1
Drugs and Mode of Action
Drug(s) KH-902 Drug Info Phase 3 Diabetic macular edema [523629]
ASP-8477 Drug Info Phase 2 Neuropathic pain [524649]
BFH-772 Drug Info Phase 2 Psoriasis [523654]
XL-820 Drug Info Phase 2 Solid tumours [522178]
AG-013958 Drug Info Phase 1/2 Age related macular degeneration [521610]
VEGF-2 gene therapy Drug Info Phase 1 Diabetic neuropathy [534594]
HuMV833 Drug Info Discontinued in Phase 1 Cancer [547036]
AZD-9935 Drug Info Terminated Solid tumours [547683]
Genevx Drug Info Terminated Angina pectoris [547116]
RG-8803 Drug Info Terminated Diabetic retinopathy [546922]
ZD-4190 Drug Info Terminated Solid tumours [546662]
Inhibitor AG-013958 Drug Info [544034]
RG-8803 Drug Info [551906]
XL-820 Drug Info [550402]
Modulator ASP-8477 Drug Info [524649]
Genevx Drug Info [549790]
KH-902 Drug Info [531802]
VEGF-2 gene therapy Drug Info [534161]
ZD-4190 Drug Info [525712]
Antagonist AZD-9935 Drug Info [550140]
Agonist BFH-772 Drug Info [550850]
Pathways
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Focal adhesion
Transcriptional misregulation in cancer
Rheumatoid arthritis
References
Ref 521610ClinicalTrials.gov (NCT00090532) A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration. U.S. National Institutes of Health.
Ref 522178ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health.
Ref 523629ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health.
Ref 523654ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health.
Ref 524649ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
Ref 534594Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998 Mar 31;97(12):1114-23.
Ref 546662Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009540)
Ref 546922Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158)
Ref 547036Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394)
Ref 547116Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013170)
Ref 547683Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)
Ref 524649ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
Ref 525712ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5.
Ref 526435Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93.
Ref 531802Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
Ref 534161Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996 Aug 10;348(9024):370-4.
Ref 544034Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
Ref 549790Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury. Circulation. 2005; 112: 2477-2486.
Ref 550140WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
Ref 550402National Cancer Institute Drug Dictionary (drug id 452042).
Ref 550850CA patent application no. 841416, Method of selecting therapeutic indications.
Ref 551906US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.